

## List of experts IMI2 – 2016

Last name	First name	Nationality	Area of expertise
Abraham	Ivo	BE	Neurodegenerative diseases
Aguado de Ros	Maria Teresa	ES	Neurodegenerative diseases
Aguado de Ros	Maria Teresa	ES	Vaccine   Epidemiology   Public health
Alarcón	Graciela	US	Lupus
Aldskogius	Håkan	SE	Vaccine
Amit	Doron	IL	Neurodegenerative diseases
Asturias	Edwin	US	Paediatrics   Vaccine research and policies
Avendano	Cristina	ES	Oncology
Aydin-Son	Yeşim	TR	Pharmacovigilance
Barker	Kate	UK	Biology
Barratt Johnson	Malcom	UK	Science and research policy
Bax	Richard	UK	Antimicrobial resistance
Bayer	Thomas	DE	Medical and Regulatory Affairs
Bell	Cindy	CA	Psychiatry
Bennett	Kathleen	IE	Research programs
Berdaï	Driss	FR	Regulatory
Bernabe	Rosemarie	NL	Pharmacology
Beronius	Karoline	SE	ICT healthcare logistics   Child health   Health service delivery in underserved areas
Bertoux	Maxime Louis	FR	Patient engagement
Bjornerud	Atle	NO	Clinical Neurosciences
Bolboaca	Sorana Daniela	RO	Physics   Imaging   Toxicology   Ethics
Borm	Paul	NL	Evidence-based medicine and evidence-based practice
Bostrom	Stig	SE	Biology   Toxicology   Cardiology
Bozzi	Yuri	IT	Neurodegenerative diseases
Bresjanac	Maja	SI	Biochemistry   Drug discovery & development   New therapeutic principles & mechanisms
Bressler	Susan	US	Neurodegenerative diseases
Brunak	Søren	DK	Biomedical informatics   Systems biology
Brunner	Daniela	AR	Ophthalmology
Bullinger	Monika	DE	Pharmacology
Caberlotto	Laura	IT	Health Outcomes   Marketing & business strategy   Medical devices
Charpak	Yves	FR	Systems biology bioinformatics
Chiotti	Anna	DK	Preventive medicine   Public health and environment   Nutrition and clinical research
Choquet	Philippe	FR	Medical and public health research
Christopher	Stephanie	US	Nuclear medicine   Preclinical imaging
Connolly	Mark	US	Patient preference assessment   Benefit-risk analysis

Last name	First name	Nationality	Area of expertise
			Medical devices
Connolly	Mark	US	Health economics & pharmacology
Coulter	Angela	UK	Health economics   Pharmacology
Cox	Anthony	UK	ADR reporting
Cramer	Philippe	FR	Chronic disease   Patient engagement
Crusio	Wim	NL	Immunology
Czarka	Mark	BE	Neurodegenerative diseases
Da Silva Lima	Beatriz	PT	Pharmacology   Pharmacogenomics   Drug discovery and design   Drug therapy
Dalla	Christina	EL	Market Access and Medical Regulatory
Denniston	Alastair	UK	Pharmacology   Neuroscience
Diez-Domingo	Javier	ES	Ophthalmology
Djambazov	Slaveyko	BG	Vaccine
Donado-Campos	Juan de Mata	ES	Oncology   Pharmacoeconomics
Dull	Peter	US	Vaccine   Public health
Dumyati	Ghinwa	US	Vaccine
Fabbretti	Elsa	IT	Public Health
Finne-Soveri	Harriet	FI	Geriatric medicine; Elderly care services
Fontana	Luis	ES	Pain
Forsse	Erik	SE	NAFLD   Liver disease   Cell therapy
Garcia-Nogales	Paula	ES	Basic biology & genetics   Life sciences research and education
Geldmacher	Christoph	DE	Animal models of pain
Girach	Aniz	UK	Immunology   Vaccine
Glasova	Helena	SK	Ophthalmology
Golubnitschaja	Olga	DE	Electrography of liver   NASH   Fibrosis
Gonzalez Borroto	Jorge	ES	Diabetes
Gozes	Ilana	IL	Toxicology
Gullien	Javier	ES	Neurodegenerative diseases
Guns	Pieter-Jan	NL	Care and use of animals in research
Guojun	Bu	US	Toxicology and imaging
Haeffner-Cavaillon	Nicole	FR	Key opinion leader ApoE biology   Neurodegenerative diseases
Hagan	James	UK	Sciences Immunology
Hamar	Peter	HU	Neurodegenerative diseases
Härter	Martin	DE	Immunology
Hartvig	Line	DK	Evidence based medicine
Hayes	Ian	UK	Cardiology   Oncology
Heemskerk	Frank	NL	Biochemistry   Immunology   Rare Diseases   Drug Discovery & development   Oncology Inflammatory Disease
Herrenknecht	Kurt	DE	Research & Development; Project Management; Product Management; Business Development and Sales

Last name	First name	Nationality	Area of expertise
Herron-Marx	Sandra	UK	Vaccine   Immune Therapy   Health sciences  Pharmacology
Herrup	Karl	US	Patient engagement
Hilt	Dana	US	MD Neurology
Hogervorst	Eva	NL	Neurodegenerative diseases
Hoglund	Kina	SE	Health Sciences
Holtorf	Anke	DE	Neurodegenerative diseases
Holz	Josefin-Beate	DE	Biotechnology   Data management and biostatistics   Clinical drug development
Honkakoski	Paavo	FI	Health Sciences
Hoppe	Nils	DE	Toxicology
Houghton	James A	IE	Ethics   Health policy
Ijzerman	Maarten	NL	Biotechnology
Inchauspé	Geneviève	FR	Health economics
James	Ed	UK	Vaccine   Immunology
Janer	Gemma	ES	Cancer Immunology
Jaworska	Joanna	PL	Toxicology
Jazbec	Janez	SI	Modelling and simulation
Jochmans	Dirk	BE	Paediatric Oncology
Justo	Nahila	SE	Drug discovery
Kemp	Graham	UK	Economic evaluation of health technologies   Oncology   Neurodegenerative and Cardiovascular Diseases
Kjær	Svend	DK	Muscle and fat metabolism   Liver disease
Klener	Pavel	CZ	Biology
Klersy	Catherine	FR	Oncology
Koenig	Franz	AT	Cardiology   Epidemiology
Kohl	Matthias	DE	Adaptive Designs
Lambert	Marie-Laurence	BE	Computational Biology Systems
Lawler	Mark	IE	Health care   Infections
Lehmann	Hans	DE	Bio banking   Oncology   Drug discovery
Lo	Donald	US	Neurodegenerative diseases
Long	Rajakumari	UK	Neurodegenerative diseases
Lotersztajn	Sophie	FR	Neurodegenerative diseases
Lynch	Marina	IE	NASH   Cell biology   Animal models
Malik	Afshan	UK	Neurodegenerative diseases
Marusic	Ana	HR	Diabetes
Mastrangelo	Peter	CA	Biomedicine and Health   Immunology
Maton-Howarth	William	UK	Biological sciences   Health & Medical sciences   Neurosciences
McKay	Gareth	IE	Medical Devices
Mets	Tony	BE	Gerontology & Geriatrics
Miller	Elizabeth	UK	Epidemiology   Public health

Last name	First name	Nationality	Area of expertise
Miranda	Joana	PT	Ophthalmology   Diabetes
Morisetti	Alberto	IT	Toxicology
Nagy	Balazs	HU	Pharmacology   Regulatory   Toxicology
Neagu	Daniel	UK	Health technology assessment
Nykanen	Pirkko	FI	Computer Science & Engineering
Obermayr	Franz	AT	SME drug development; Oncology antibiotics
Oyvind	Hope	NO	Data Privacy
Papa-Konidari	Anna	EL	Health technology assessment
Paz	Maria Fe	ES	Microbiology   Virology
Penn	Charles	UK	Antibiotic resistance
Perola	Markus	FI	Genomics
Pfleiderer	Michael	DE	Evaluation of vaccines
Pietrini	Pietro	IT	Personalised medicine   Translational medicine   NASH   Liver disease
Pitter	Janos	HU	Health economics
Pitzalis	Costantino	IT	Brain networks
Pouzet	Bruno	FR	Immunology   Rheumatology
Pruna	Simion	RO	Drug discovery   Animal models
Purves	John	UK	Former EMA officer for biological and biotechnology products
Reed	Zarifah		Emerging diseases with public health impact
Riddell	John	UK	Health technology assessment
Rissanen	Aila	FI	Obesity research
Roess	Amira	US	Pain
Roncaglioni	Alessandra	IT	Vaccine
Roncarati	Renza	IT	Toxicology
Rooväli	Liis	EE	Health sciences
Rossetti	Maura	IT	Neurodegenerative diseases
Ruch	Patrick	CH	IT   Social media
Ruiz	Sol	ES	Biotechnology   Advanced Therapies
Rusu	Adriana	RO	Immunity
Salminen	Lotta	FI	Diabetes
Santanello	Nancy	US	Epidemiology
Santoro	Nicola	IT	Liver disease
Sanz-Requena	Roberto	ES	Paediatric diseases
Schulte in Baume	Tobias	DE	Oncology   Ethics
Schwede	Torsten	CH	Bioinformatics & knowledge management
Scudeller	Luigia	IT	Health and Medical Law   Genetic Data
Seow	Kah-Tong	MY	Clinical Epidemiology   Evidence Based Medicine
Sjögren	Magnus	SE	Systems biology bioinformatics
Skinner	Nigel	UK	Clinical Development   Neuroscience

Last name	First name	Nationality	Area of expertise
Sol Ruiz	Maria	ES	Drug Discovery
Spetz	Anna-Lena	SE	Biotechnology   Advanced Therapies
Sterba	Jaroslav	CZ	Adaptive immunity   Vaccine
Tenson	Tanel	EE	Antibiotic resistance
Tesar	Vladimir	CZ	Paediatric Oncology
Thiry	Georges	BE	Cardiovascular diseases
Thomsen	Mogens	DK	Vaccine
Tieu	Kim	CA	Medical Research
Toivonen	Markku	FI	Neurodegenerative diseases
Tomori	Oyewale	NG	Infectious Diseases   Vaccine
Topouzis	Fotis	EL	Ophthalmology
Tringali	Michele	IT	Ophthalmology
Trněný	Marek	CZ	Gastroenterology
Tsiknakis	Manolis	EL	Biomedical informatics
Tsintis	Panos	CY	Oncology
Turk	Eva	SI	Pharmacovigilance
Van Broeckhoven	Christine	BE	Patient engagement
Van den Berg	Bernardus	NL	Health sciences
Van Hoef	Marlies	NL	Oncology
Vanderheyden	Jean-Luc	BE	Imaging   Ophthalmology
Vardakas	Konstantinos	EL	Antimicrobial resistance
Vellinga	Akke	NL	Antimicrobial resistance
Voineskos	Aristotle N.	CA	Understanding genetic and structural brain determinants of brain function
Von frenckell	Remy	BE	Biostatistics   Clinical trials
von Frenckell	Remy	BE	Epidemiology
Watts Bush	Karen	US	Antibacterial drug discovery
Weber	Jonathan	UK	Infectious Diseases   Vaccine
Widdowson	Marc-Alain	UK	Infectious Diseases   Vaccine
Wikström	Ann-Charlotte	SE	Clinical Immunology
Williams	Anwen	UK	Rheumatology
Windisch	Manfred	AT	Neurodegenerative diseases
Worthington	Jane	UK	Rheumatoid Arthritis
Wylegala	Edward	PL	Ophthalmology
Wyska	Elzbieta	PL	Pharmacology
Zaragoza Domingo	Silvia	ES	Neurodegenerative diseases
Zinner	Stephen H.	US	Antimicrobial resistance   Clinical trials
Zwierzina	Heinz	AT	Haematology   Oncology